The DEAK-Transplant Study - Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?
Kidney transplantation is the preferred kidney replacement therapy (KRT) modality for eligible patients with end-stage kidney disease. However, gradual loss of kidney graft function is a clinical problem, increasing the need for resource demanding retransplantations and dialysis. Both immunological and non-immunological causes are involved. Recent trials have repeatedly confirmed that sodium glucose co-transporter 2 inhibitors (SGLT2i) may slow the rate of eGFR decline in CKD patients with and without diabetes. However, whether this translates to recently transplanted patients is unknown.
The “Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?” Study (the DEAK-Transplant Study) is a national multicenter double-blind randomized controlled trial testing whether the GFR decline in recently kidney transplanted patients is slower in patients receiving dapagliflozin compared to those receiving placebo. Our research group participates actively in the study, and in a post-doc project we specifically study whether an eventual effect of dapagliflozin in part can be explained by improved blood pressure control and blood pressure variability.
In the same postdoc project, we also study changes in autonomic function in kidney transplant patients over the first year posttransplant, using data from the Norwegian Renal Registry.
National Principal Investigator: Professor Anders Åsberg, UiO